TTNP — Titan Pharmaceuticals Cashflow Statement
0.000.00%
- $5.60m
- $1.51m
- $0.18m
Annual cashflow statement for Titan Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -16.5 | -18.2 | -8.78 | -10.2 | -5.57 |
Depreciation | |||||
Non-Cash Items | -0.192 | -0.271 | 0.875 | 1.45 | -0.719 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.961 | 1.02 | -0.219 | 0.378 | -0.916 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -15.4 | -17.2 | -7.9 | -8.18 | -7.09 |
Capital Expenditures | -0.256 | -0.54 | -0.023 | 0 | -0.002 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | — | — | 0.734 |
Sale of Fixed Assets | |||||
Cash from Investing Activities | -0.256 | -0.54 | -0.023 | 0 | 0.732 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 11.3 | 17.9 | 8.84 | 4.98 | 10 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -4.43 | 0.19 | 0.919 | -3.2 | 3.64 |